# NIA Awards $2.5M Grant to Constantiam Biosciences

The National Institute on Aging (NIA) awarded Constantiam Biosciences a **$2.5 million Phase II SBIR grant** in 2024 to scale and commercialize its MAVEvidence platform, which interprets genetic variants associated with Alzheimer's disease. This funding supports expanding gene coverage, enhancing data curation tools, and validating clinical utility over a two-year period. This grant represents a significant opportunity for diagnostics and biotech firms focused on neurodegenerative diseases and precision medicine.

- The award highlights federal investment in advanced genetic testing technologies for Alzheimer's, signaling growing procurement opportunities in neurogenetics.
- Companies specializing in genetic variant interpretation and clinical diagnostics should evaluate partnerships or technology development aligned with the MAVEvidence platform's capabilities.
- Procurement professionals should note the emphasis on clinical validation and scalability, indicating future contract opportunities may require demonstrated end-user effectiveness.
- The location in Watertown, Massachusetts, underscores the region's role as a biotech innovation hub relevant for industry engagement and collaboration.

**Jurisdictions:** federal
**Industries:** Healthcare, Information Technology
**Topics:** Grants & Funding, Artificial Intelligence
**Published:** September 24, 2026

### Government Entities
- National Institute on Aging (NIA)
- National Human Genome Research Institute (NHGRI)

### Vendors
- Constantiam Biosciences (awardee)

### Key Quotes
> Phase I was about proving the concept on a small set of genes, while Phase II is about scaling to a commercial product and validating it with end users in the field.
> — Norman Ong, Cofounder

### Sources
- [Constantiam lands $2.5M NIH grant to scale Alzheimer's risk test | Dealroom.co](https://app.dealroom.co/news/note/constantiam-lands-2-5m-nih-grant-to-scale-alzheimer-s-risk-test) - Dealroom